Last reviewed · How we verify
Transfusion of 7-day stored red blood cells
Transfusion of 7-day stored red blood cells is a Biologic drug developed by Stony Brook University. It is currently FDA-approved.
The transfusion of 7-day stored red blood cells, marketed by Stony Brook University, holds a unique position in the blood transfusion market. A key strength is the extended storage period, which can enhance inventory management and reduce waste. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition.
At a glance
| Generic name | Transfusion of 7-day stored red blood cells |
|---|---|
| Sponsor | Stony Brook University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Impact of Red Cell Storage Age
- Transfusion of Biotin-Labeled Red Blood Cells (PHASE2)
- Age of Blood in Children in Pediatric Intensive Care Units (PHASE3)
- VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained? (PHASE4)
- Age of Red Blood Cells in Premature Infants Study (ARIPI) (NA)
- Fresh Versus Old Red Blood Cells for Transfusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfusion of 7-day stored red blood cells CI brief — competitive landscape report
- Transfusion of 7-day stored red blood cells updates RSS · CI watch RSS
- Stony Brook University portfolio CI